Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8625 - 8632 of 12086 results
Lost Profit Damages: Key Massachusetts Appellate Cases
February 11, 2016| News
Negative Assurance Letters in EB-5 Offerings
February 11, 2016| News
Subsidizing Student Health Insurance With Stipends – New Agency Guidance and Relief (Employment Matters)
February 10, 2016| Blog| Viewpoint
2016 ALTA/NSPS (formerly ALTA/ACSM) Land Title Survey Standards
February 10, 2016| Blog| Viewpoint
Solar Installation Boom Expected to Continue in 2016
February 10, 2016| Blog| Viewpoint
Deciphering the Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers
February 10, 2016| Advisory| Viewpoint
Amended version of Judicial Redress Act passes the Senate; now goes back to the House
February 10, 2016| Blog| Viewpoint
CMS Takes Action Against Network Transparency While New Jersey Legislation Hits a Snag
February 10, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|